Maia Wealth LLC Invests $272,000 in Sanofi (NASDAQ:SNY)

Maia Wealth LLC acquired a new stake in Sanofi (NASDAQ:SNY) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,716 shares of the company’s stock, valued at approximately $272,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SNY. Allspring Global Investments Holdings LLC grew its position in Sanofi by 773.4% in the first quarter. Allspring Global Investments Holdings LLC now owns 5,651 shares of the company’s stock worth $275,000 after acquiring an additional 5,004 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Sanofi by 7.1% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,618 shares of the company’s stock worth $2,411,000 after purchasing an additional 3,268 shares during the period. Larson Financial Group LLC increased its position in shares of Sanofi by 480.8% during the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock worth $29,000 after purchasing an additional 500 shares during the last quarter. Geneos Wealth Management Inc. increased its position in shares of Sanofi by 9.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 7,063 shares of the company’s stock worth $343,000 after purchasing an additional 582 shares during the last quarter. Finally, Gallacher Capital Management LLC raised its holdings in Sanofi by 14.4% in the 1st quarter. Gallacher Capital Management LLC now owns 6,686 shares of the company’s stock valued at $325,000 after buying an additional 843 shares during the period. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Trading Down 3.0 %

Shares of SNY stock opened at $51.26 on Thursday. Sanofi has a fifty-two week low of $45.00 and a fifty-two week high of $58.97. The company has a 50 day moving average price of $55.78 and a 200 day moving average price of $52.15. The stock has a market capitalization of $130.09 billion, a P/E ratio of 26.15, a price-to-earnings-growth ratio of 1.35 and a beta of 0.61. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. The business had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company’s revenue was up 12.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.55 earnings per share. Equities research analysts predict that Sanofi will post 4.27 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on SNY. Argus increased their target price on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday. Finally, Citigroup raised Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Sanofi currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.